COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics
Top Cited Papers
- 18 March 2020
- journal article
- review article
- Published by Taylor & Francis Ltd in Human Vaccines & Immunotherapeutics
- Vol. 16 (6), 1232-1238
- https://doi.org/10.1080/21645515.2020.1735227
Abstract
The novel coronavirus infection (COVID-19 or Coronavirus disease 2019) that emerged from Wuhan, Hubei province of China has spread to many countries worldwide. Efforts have been made to develop vaccines against human coronavirus (CoV) infections such as MERS and SARS in the past decades. However, to date, no licensed antiviral treatment or vaccine exists for MERS and SARS. Most of the efforts for developing CoV vaccines and drugs target the spike glycoprotein or S protein, the major inducer of neutralizing antibodies. Although a few candidates have shown efficacy in in vitro studies, not many have progressed to randomized animal or human trials, hence may have limited use to counter COVID-19 infection. This article highlights ongoing advances in designing vaccines and therapeutics to counter COVID-19 while also focusing on such experiences and advances as made with earlier SARS- and MERS-CoVs, which together could enable efforts to halt this emerging virus infection.Keywords
Funding Information
- stated
This publication has 78 references indexed in Scilit:
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- A Live Attenuated Severe Acute Respiratory Syndrome Coronavirus Is Immunogenic and Efficacious in Golden Syrian HamstersJournal of Virology, 2008
- Animal models and vaccines for SARS-CoV infectionVirus Research, 2008
- Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoVJournal of Medical Virology, 2006
- Animal models and antibody assays for evaluating candidate SARS vaccines: Summary of a technical meeting 25–26 August 2005, London, UKVaccine, 2006
- Mucosal Immunization with Surface-Displayed Severe Acute Respiratory Syndrome Coronavirus Spike Protein onLactobacillus caseiInduces Neutralizing Antibodies in MiceJournal of Virology, 2006
- SARS Vaccine DevelopmentEmerging Infectious Diseases, 2005
- Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in miceVaccine, 2005
- Retroviruses Pseudotyped with the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Efficiently Infect Cells Expressing Angiotensin-Converting Enzyme 2Journal of Virology, 2004
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature, 2004